Articles tagged with Drug Resistance
Researchers at UCSF identified a biological escape hatch that explains resistance to targeted drug treatment in lung cancer patients. Combining two compounds, erlotinib and PBS-1086, effectively wipes out cancer cells in mice implanted with cells from drug-resistant tumors.
A new engineered protein-based medicine has been shown to overcome radiation resistance in leukemia by selectively binding to leukemia cells and amplifying the potency of radiation therapy. In mouse models, this precision medicine improved survival rates in aggressive human leukemia with minimal side effects.
Researchers at Oregon State University have discovered a group of genes in snails that provide natural resistance to the flatworm parasite causing schistosomiasis. This finding offers potential new avenues for treatment and control of the disease, which can cause chronic disability and even lead to bladder cancer.
Researchers discover roflumilast's mechanism of tolerance in severe COPD patients, highlighting potential for new therapeutics to improve efficacy. The study identifies key protein PKA-Cβ as a target for reducing unwanted PDE4B2 production.
India's TB epidemic is worsened by the failure of its Revised National Tuberculosis Control Program to engage the private sector, argues Dr. Zarir Udwadia. The program needs to provide free diagnosis and treatment to all patients, regardless of sector, to control the spread of TB.
Researchers have identified a compound that blocks HIV entry by targeting both CCR5 and CXCR4, reducing the risk of resistance and making treatment more effective. This finding has significant implications for the development of new HIV treatments and could potentially keep treatment affordable for millions in the developing world.
Researchers use mathematical models to characterize tumor microenvironment, highlighting sanctuary sites as key to drug resistance. Tumor sanctuaries with little drug exposure are the source of resistant mutants.
The study uses mutant stem cells to screen for genes involved in rabies infection and identifies 63 host target genes that can be targeted for treatment. The technique has potential applications in discovering gene function and assessing human host response to various infections and toxins.
Researchers at SDSC and UCSD have described the molecular mechanism of cancer development caused by well-known EGFR mutations in non-small cell lung cancer. Computer modeling elucidated their molecular mechanism of action, suggesting that antibodies targeting dimerization would be effective treatments.
A new platform developed by UCLA bioengineers uses nanotechnology-enhanced medications and AI-driven analysis to create safer and more effective treatments for drug-resistant tumors. The approach, called Feedback System Control.II, has been shown to outperform traditional combination therapies.
Researchers at MD Anderson Cancer Center have identified unique 'protein patterns' in melanoma patients to predict resistance to BRAF inhibitors. These patterns may help guide personalized treatment decisions, including targeted agents or immunotherapies.
A study found that individuals exhibiting resistance to aspirin have more severe strokes, with larger brain areas affected, compared to those who respond to the drug. The study also found a median stroke severity score of four in the aspirin-resistant group, indicating a moderate stroke.
A study confirmed artemisinin-resistant malaria parasites in Homalin, Sagaing Region, Myanmar, just 25km from the Indian border. This finding poses a significant threat to global control and eradication of malaria, as drug resistance spreads from Asia to Africa and potentially emerges independently.
Researchers at the University of Toronto found that only a few strains of Candida albicans became resistant to combination therapy, and that resistance came at a cost to the fungus. The resistant strains grew poorly in stress conditions and were vulnerable to immune cells.
Researchers found that non-mutated CLL shows increased gene expression variability, while mutated leukaemia has lower variability. This variation is linked to tumour aggressiveness and may help predict disease subtype.
Researchers at Dartmouth's Norris Cotton Cancer Center have identified ERBB4 as a driver protein in breast cancers that have developed resistance to HER2 targeted therapies. The discovery suggests that anti-ERBB4 drugs could be highly beneficial for patients who no longer respond to first or second-line treatments.
A genome-wide study of the malaria parasite reveals a complex genetic architecture that enables artemisinin resistance. Researchers found 20 mutations in the kelch13 gene and four other genes that work together to support resistance, but monitoring specific genetic backgrounds could help target high-risk regions.
Moffitt researchers found that high activity of cell surface protein EphA2 leads to aggressive behavior in melanoma cells treated with B-Raf inhibitor drugs. Targeting EphA2 may prevent disease progression and improve treatment outcomes for patients.
Researchers at UMass Amherst found a whole plant therapy more effective than purified drug artemisinin in killing malaria parasites, even those resistant to the pharmaceutical treatment. The study suggests using the whole plant may be a sustainable alternative for treating human malaria.
A team of researchers at Duke University Medical Center has identified key events that lead to cancer cell resistance to drugs. By understanding these pathways, they can develop strategies to block them and keep current therapies effective.
A recent study found that cystic fibrosis patients are at a higher risk of developing ganciclovir-resistant cytomegalovirus strains due to insufficient levels of the drug in their system. This can lead to delayed or inadequate response to treatment, highlighting the need for closer monitoring and therapeutic level adjustments.
Scientists have discovered that Metformin can boost the efficacy of TB medication and stop Mtb replication without promoting drug resistance. This discovery could lead to a new and affordable treatment strategy for tuberculosis, potentially shortening clinical trials.
A study published in Science has identified a single mutated gene, K13, as the cause of growing resistance to malaria drugs in Southeast Asia. This finding provides a way to detect emerging resistance and potentially eliminate it before spreading globally.
A new family of cancer drugs targeting multiple key proteins could treat incurable skin cancers. The panRAF inhibitors showed effectiveness in patients with melanoma resistant to BRAF inhibitors.
NTU scientists have identified two major ways malaria parasites become resistant to Artemisinin, a key front-line drug. The breakthrough findings will help doctors design new treatment cocktails and monitor drug resistance more effectively.
Researchers have identified a novel therapeutic approach using gamma secretase inhibitors (GSI) to inhibit Notch and block critical genes involved in tumor growth. The study suggests that GSI may optimize existing endocrine therapies and overcome resistance to cancer drugs.
Researchers at MIT have successfully turned on any desired gene in living cells using the CRISPR/Cas9 system. This breakthrough enables scientists to study gene function and identify genes involved in diseases, such as melanoma. The new method has also been used to screen for genes that confer resistance to cancer drugs.
Researchers found that HSP90 inhibition increases the ability of anti-estrogen agents to block cell cycle progression, thereby thwarting replication of tumor cells. The study provides a strong rationale for combining HSP90 inhibitors with hormonal therapy in ER+ breast cancer treatment.
Researchers have developed a novel approach to drug screening that could more precisely tailor chemotherapy to a patient's individual blood cancer type. By correcting for the matrix effect, Shin and Mooney believe their approach could identify a subset of drugs that will be more likely to be effective against chronic myeloid leukemias.
Scientists have identified a range of new chemicals with potent anti-malarial properties that could lead to new treatments for the disease. The compounds block a molecular salt pump at the surface of the parasite, causing it to swell and burst.
A phase I clinical trial has demonstrated that ASP8273 causes tumour shrinkage in patients with treatment-resistant non-small cell lung cancer (NSCLC) who have both the EGFR and T790M mutations. The overall response rate is 78%, comparable to other drugs in development.
Researchers have uncovered a mechanism that explains why many ALS drugs fail as the disease progresses: the brain's pumps become more active and remove both toxins and medicine. Blocking these pumps improves drug efficacy in mouse models.
Researchers found galeterone to be effective in lowering PSA levels and stabilizing disease in patients with CRPC. The drug showed promising activity against the AR-V7 variant, a mechanism of resistance in this disease.
Researchers at EPFL have identified an alternative part of Abl-kinase on which drugs can bind with reduced risk of drug resistance. This new approach may overcome the problem of tumor drug resistance, offering a potential treatment for chronic myeloid leukemia.
Researchers at Massachusetts General Hospital describe a new screening platform that combines genetic and pharmacologic screening of tumors, enabling truly individualized treatment regimens. The approach identifies previously unknown resistance mechanisms, several of which were not detectable by gene sequencing alone.
Researchers found that simple text messages can help patients complete their full malaria medication regimen, boosting rates of treatment completion and reducing the risk of drug-resistant diseases. The study used SMS reminders in Ghana and showed a significant impact on treatment adherence.
Researchers at the Salk Institute have discovered a mechanism for cancer cells to become resistant to chemotherapy, which may lead to a new approach to treating cancer. The study found that variations in breast cancer cells' RNA enable the cancer to evolve and adapt more quickly than previously thought.
The American Academy of Neurology states that the risk of death, overdose, addiction, or serious side effects from prescription opioids exceeds their benefits in treating chronic, non-cancerous conditions. The AAN recommends safer prescribing practices to minimize risks.
The IMPRESS trial found that continued gefitinib therapy after resistance development in lung cancer did not improve progression-free survival. Chemotherapy alone remains the standard treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Researchers propose epigenetic drugs to treat cancer resistance and relapse by modifying gene expression. Studies suggest epigenetic changes contribute to cancer progenitor cell formation, drug resistance, and relapse.
A group of researchers recommend applying evolutionary biology to combat modern threats, proposing gene therapies, drought-resistant crop varieties, and conservation strategies to protect land with high genetic diversity. This approach can help develop more robust solutions to societal problems and promote sustainable development.
A new study from Washington State University found that estrogen levels significantly increase tolerance to THC in female rats, making them more vulnerable to negative side effects. The research suggests that women are at higher risk of experiencing anxiety, paranoia, and addiction when using cannabis.
EPFL researchers developed a synthetic amino acid that can impact 3D structure of bioactive peptides, enhancing their potency. The amino acid, similar to cysteine, forms bridges influencing overall structure and function of peptides and proteins.
Patients with resistant hypertension have higher risks for cardiovascular events than those with non-resistant hypertension, with elevated risks mainly contributing to increasing stroke events. Subgroup analysis showed that resistant hypertension increased the risks of stroke in females by 35% and in elderly patients by 20%.
Experts say 14th century Venice's response to the plague holds lessons on how to mitigate the consequences of today's emerging threats. The city's use of resilience management, including physical movement management and quarantine measures, can inform strategies for dealing with highly infectious diseases like Ebola.
Resistant hypertension is a condition affecting 20% of Canadian adults with high blood pressure, characterized by elevated blood pressure despite treatment. Structured approaches, including medication optimization and lifestyle modifications, are recommended for effective management.
A strong association has been found between severe untreated obstructive sleep apnea and the risk of elevated blood pressure despite aggressive medication use. The odds of resistant elevated blood pressure were four times higher in participants with severe sleep apnea.
Researchers developed a new computational method to study disease-causing genes, starting with Plasmodium falciparum malaria. The method allowed for the prediction of protein functions and revealed the role of EXP1 in detoxifying metabolic byproducts and drug susceptibility.
Researchers at Saint Louis University have trapped the part of a virus responsible for inserting its DNA into human cells, a crucial step in understanding how HIV infects people. By capturing integrase with x-ray crystallography, scientists aim to develop new treatments and better understand how existing drugs work.
A new study published in PLOS Medicine found that treating young children with dihydroartemisinin-piperaquine (DP) decreases their risk of contracting malaria. The study showed a protective efficacy of 58% against malaria episodes, making DP a promising alternative to current treatments.
Artemisinin resistance has become widespread in Southeast Asia, particularly in Cambodia, Myanmar, Thailand, and Vietnam. A six-day course of artemisinin-based combination therapy proved highly effective in treating drug-resistant malaria cases.
Researchers found that some microorganisms can use epimutations, a temporary silencing of drug targets, to gain drug resistance without committing to permanent mutations. This flexible mechanism could be employed by various organisms to withstand treatment with different drugs.
A new study by Tulane University reveals that exposure to light at night can render breast cancer cells resistant to tamoxifen. In contrast, complete darkness and high melatonin levels significantly slow tumor growth and enhance tamoxifen's effectiveness.
Researchers at H. Lee Moffitt Cancer Center & Research Institute developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze biomarkers in blood and tissue, helping identify therapeutic targets for melanoma treatment. The study identified alterations in cell signaling pathways in drug-resistant cells.
University of Chicago scientists have developed new multiscale simulations that reveal the proton permeation mechanism in influenza A, a crucial step in viral replication. This breakthrough could lead to the development of more effective and targeted treatments against the flu.
Scientists have identified a new biomarker called Neuromedin U (NmU) that may help predict and overcome resistance to newer anti-cancer drugs for HER2 positive cancers. The discovery could lead to more effective treatment strategies and improved patient outcomes.
Researchers have discovered that over-expression of Cripto-1 makes lung cancer cells resistant to erlotinib, a widely used targeted therapy. Blocking Cripto-1 signaling restored sensitivity to the drug in cell lines and animals, suggesting a potential reversal mechanism.
Researchers from the University of Freiburg have made significant progress in understanding how the antimalarial drug atovaquone works. By analyzing its molecular structure, they have identified key binding sites and revealed the underlying mechanism of resistance to mutations. This breakthrough could lead to the development of more ef...
Researchers at the University of Manchester have discovered how melanoma drugs can lead to cancer progression when treatment is stopped. Using a combination of BRAF and MEK inhibitors shows promise in combating drug resistance in advanced metastatic melanoma.
A new study has discovered how ibrutinib resistance develops in CLL patients, identifying key gene mutations that weaken the drug's ability to bind with Bruton's tyrosine kinase. This understanding is crucial for developing effective alternative treatments for patients who develop resistance.